Literature DB >> 32410325

AMD Management During the COVID-19 Pandemic.

Donato Colantuono1, Alexandra Miere1,2, Oudy Semoun1, Francesca Amoroso1, Eric H Souied1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32410325      PMCID: PMC7273087          DOI: 10.1111/aos.14469

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


× No keyword cloud information.
Editor, At the end of 2019, a novel betacoronavirus (SARS‐CoV‐2) was identified and subsequently led to the ongoing COVID‐19 pandemic. This respiratory virus, leading to pneumonia, severe acute respiratory syndrome (SARS) and even death, has emerged in Wuhan, China, and then spread worldwide at tremendous speed (Ashour et al., 2020), becoming in March 2020 a public health problem even in France. The novel coronavirus appears to be highly contagious, particularly by respiratory droplets, the major mode of diffusion besides discharges and conjunctival secretions (Wang et al., 2020). Ophthalmologists are a high‐risk category, for the daily close contact with a high volume of patients. Our department is a tertiary reference centre for the diagnosis and treatment of age‐related macular degeneration (AMD). Hence, given the higher mortality of the disease in the elderly population or in people with several comorbidities such as high blood pressure and diabetes (Chen et al., 2020), our AMD patients are particularly at risk in terms of both vital and functional prognosis. Therefore, given the importance of carry on the cares for AMD, which is one of the leading causes of central vision loss and requires periodic checks and treatments, the activity was rigorously and carefully reorganized to assure protection of both physicians and patients. According to recommendations of national (Société française d'ophtalmologie, 2020) and international (American macular degeneration foundation, 2020) ophthalmology societies, a strengthening of patient’s triage was put into place. Instructions over COVID‐19’s symptoms and prophylactic measures were introduced in waiting areas. The waiting room itself was reorganized, by positioning chairs 2 m apart from each other. Only one visitor accompanying each patient was allowed. Sanitation was enhanced with a careful and regular disinfection of surfaces. All healthcare workers were asked to wear masks, gloves and ocular shields. Concerning specifically AMD patients, there was a reorganization of the cares according to the subtype of AMD. General routine intermediate or dry AMD patient visits were rescheduled, and home monitoring (checking at least once a week Amsler grid) and healthy lifestyle choices (controlling diet and eventually continuing taking supplements) were recommended. Patients were also reassured by the fact that urgent care for AMD was assured during all the pandemic. For patients with neovascular AMD, considering that many studies have shown that maintaining a regular schedule of eye anti‐VEGF injections (IVI) is indispensable in retaining vision, the treatment was guaranteed. Therefore, a fixed treatment regimen was set up for the next 4 months both for the patients previously undergoing pro re nata (PRN) regimen, and for that having undergone Treat‐and‐Extend (T&E) regimen, after careful analysis of all the records. For T&E patients, the longest possible interval between injections (up to 12 weeks) were settled, also inviting them to perform home monitoring. Before IVI, best‐corrected visual acuity assessment, optical coherence tomography (OCT) and fundus ocular examination were avoided if not strictly necessary. Patients were informed that the doctor would have spoken as little as possible during parts of the examination, requesting them to also refrain from talking during the examination. Each patient was provided with a surgical mask before IVI. Furthermore, a retina specialist was daily available by phone in order to be able to answer all the doubts or questions that patients may have regarding their case. Despite the fear this outbreak has generated throughout the world, our patients were reassured by the fact that ophthalmological activity was continued, by the implementation of protective measures and by the presence of retina specialists ready to take care of them even in this difficult context. Given that the quality of life depends so much on preserving vision, our AMD patients should not have to choose between preserving their vision and preserving their life.
  3 in total

1.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens.

Authors:  Wenling Wang; Yanli Xu; Ruqin Gao; Roujian Lu; Kai Han; Guizhen Wu; Wenjie Tan
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

2.  Clinical Characteristics and Outcomes of Older Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective Study.

Authors:  TieLong Chen; Zhe Dai; Pingzheng Mo; Xinyu Li; Zhiyong Ma; Shihui Song; Xiaoping Chen; Mingqi Luo; Ke Liang; Shicheng Gao; Yongxi Zhang; Liping Deng; Yong Xiong
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-09-16       Impact factor: 6.053

Review 3.  Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.

Authors:  Hossam M Ashour; Walid F Elkhatib; Md Masudur Rahman; Hatem A Elshabrawy
Journal:  Pathogens       Date:  2020-03-04
  3 in total
  4 in total

1.  Drop in well-being of ARMD patients under treatment with anti-VEGF injections during the COVID-19 pandemic.

Authors:  Ioanna Mylona; Kalliopi Papadopoulou; Serafeim Roumelis; Georgios D Floros
Journal:  Int Ophthalmol       Date:  2022-04-01       Impact factor: 2.029

2.  IMPACT study: Impact of adherence to anti-VEGF intravitreal injections for macular disease during COVID 19-related confinement in France.

Authors:  Victoire Hurand; Jean-Baptiste Ducloyer; Florian Baudin; Serge Aho; Michel Weber; Laurent Kodjikian; François Devin; Pierre-Henry Gabrielle; Catherine Creuzot-Garcher; Pascale Massin
Journal:  Acta Ophthalmol       Date:  2022-06-29       Impact factor: 3.988

3.  Delayed Intravitreal Anti-VEGF Therapy for Patients During the COVID-19 Lockdown: An Ethical Endeavor.

Authors:  Mutasem Elfalah; Saif Aldeen AlRyalat; Mario Damiano Toro; Robert Rejdak; Sandrine Zweifel; Rashed Nazzal; Mohammed Abu-Ameerh; Osama Ababneh; Almutez Gharaibeh; Zuhair Sharif; Jehad Meqbil; Mo'ath AlShawabkeh; Amal Alwreikat; Muawyah Al Bdour; Maysa Al-Hussaini; Yacoub A Yousef
Journal:  Clin Ophthalmol       Date:  2021-02-17

4.  Assessment of Patients' Confidence Regarding a New Triage Concept in a Medical Retina Clinic during the First COVID-19 Outbreak.

Authors:  Anahita Bajka; Maximilian Robert Justus Wiest; Timothy Hamann; Mario Damiano Toro; Sandrine Anne Zweifel
Journal:  Int J Environ Res Public Health       Date:  2021-05-29       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.